Metabolic syndrome in schizophrenia: A comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India

Nordic Journal of Psychiatry

Volumn 66, Issue 3, 2012, Pages 215-221

  Pallava, Abhishek ^a   Chadda, Rakesh K ^a   Sood, Mamta ^a   Lakshmy, R ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Antipsychotics; India; Metabolic syndrome; Schizophrenia

Indexed keywords

CLOZAPINE; GLUCOSE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; TRIFLUOPERAZINE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY MASS; CALORIC INTAKE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; FAMILY HISTORY; FASTING BLOOD SUGAR; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INDIA; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; OUTPATIENT CARE; PREVALENCE; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; CASE-CONTROL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; INDIA; INTERNATIONAL CLASSIFICATION OF DISEASES; LIPOPROTEINS, VLDL; MALE; METABOLIC SYNDROME X; PREVALENCE; RISK; SCHIZOPHRENIA; TRIGLYCERIDES; YOUNG ADULT;

EID: 84862087069     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2011.621977     Document Type: Article

References (32)

1. Brown S. Excess mortality of schizophrenia, a meta-analysis. Br JPsychiatry 1997;171:502-8.
2. Hagg S, Lindblom Y, Mjorndal T, Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006;21:93-8. (Pubitemid 43740316)
3. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28. (Pubitemid 40523737)
4. Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin MR, Lauren LH, et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: The Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 2005;66:559-63. (Pubitemid 40733696)
5. DeHert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006;83:87-93.
6. DeHert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, et al. Typical and atypical antipsychotics differentially affect longterm incidence rates of the metabolic syndrome in fi rst-episode patients with schizophrenia: A retrospective chart review. Schizophr Res 2008;101:295-303.
7. DeHert M, Hanssens L, Wampers M, van Winkel R, Van Eyck D, Scheen A,et al. Prevalence and incidence rates of metabolic abnormalities and diabetes in a prospective study of patients treated with second-generation antipsychotics. Schizophr Bull 2007;33:497-98.
8. Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999;84:137-44. (Pubitemid 29036692)
9. Dudeja V, Misra A, Pandey RM, Devina G, Kumar G, Vikram NK. BMI does not accurately predict overweight in Asian Indians in Northern India. Br J Nutr 2001;86:105-12. (Pubitemid 32640256)
10. Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in fi rst episode schizophrenia - A randomized double-blind controlled short-term prospective study. Schizophr Res 2008;101:266-72.
11. Saddichha S, Ameen S, Akhtar S. Incidence of new onset metabolic syndrome with atypical antipsychotics in fi rst episode schizophrenia: A six-week prospective study in Indian female patients. Schizophr Res 2007;95:247. (Pubitemid 47313636)
12. Seidel HM, Ball JW, Dains JE, Benedict GW. Mosby ' s guide to physical examination. 6th edition. Philadelphia, PA: Mosby; 2006.
13. K ay SR, Fiszbein A, Opler A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76. (Pubitemid 18039085)
14. Gopalan C, Ramasastri BV, Balasubramanian SC. Nutritive value of Indian foods. New Delhi: Indian Council of Medical Research; 1989.
15. Troisi RJ, Cowie CC, Harris MI. Diurnal variation in fasting plasma glucose: Implications for diagnosis of diabetes in patients examined in the afternoon. JAMA 2000;284:3157-9. (Pubitemid 32039079)
16. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome- A new worldwide defi nition. A consensus statement from the International Diabetes Federation. Diabet Med 2005;23:469-80.
17. Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence of metabolic syndrome using WHO, ATPIII and IDF defi nitions in Asian Indians: The Chennai urban rural epidemiology study (CURES-34). Diabetes Metab Res Rev 2007;23:127-34.
18. Gupta R, Deedwania PC, Gupta A, Rastogi S, Panwar RB, Kothari K. Prevalence of metabolic syndrome in an Indian urban population. Int J Cardiol 2004;97:257-61. (Pubitemid 39286845)
19. Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA. Agespecifi c prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: The Norwegian HUNT 2 study. BMC Pub Health 2007;7:220.
20. Cerit C, Ozten E, Yildiz M. The prevalence of metabolic syndrome and related factors in patients with schizophrenia. Turk J Psychiatry 2008;19:124-32.
21. Heiskanen T, Niskanen L, Lyytikäinen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-9. (Pubitemid 36618288)
22. Teixeira PJR, Rocha FL. The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Revista Brasileira de Psiquiatria 2007;29:330-6. (Pubitemid 351358057)
23. Weiden PJ, Daniel DG, Simpson G, Romano SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 2003;23:595-600. (Pubitemid 37443191)
24. Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, Ingenito GG. Switching patients to aripiprazole from other antipsychotic agents: A multicenter randomized study. Psychopharmcology (Berl) 2003;166:391-9. (Pubitemid 36469941)
25. Arango C, Bobes J, Aranda P, Carmena R, Garcia M, Rejas J. Acomparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study. Schizophr Res 2008;104:1-12.
26. Kahn R, Buse J, Ferrannini E, Stern M. American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: Time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-304. (Pubitemid 41242486)
27. Kato MM, Currier MB, Gomez CM, Hall L, Gonzalez-Blanco M. Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry 2004;6:74-7.
28. Al-Sarraj T, Saadi H, Volek JS, Fernandez ML. Metabolic syndrome prevalence, dietary intake, and cardiovascular risk profi le among overweight and obese adults 18-50 years old from the United Arab Emirates. Metab Syndr Relat Disord 2010;8:39-46.
29. Straker D, Correll CU, Kramer-Ginsberg E, Abdulhamid N, Koshy F, Rubens E, Saint-Vil R, Kane JM, Manu P. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 2005;162:1217-21. (Pubitemid 40770711)
30. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
31. Savoy YE, Ashton MA, Miller MW, Nedza FM, Spracklin DK, Hawthorn MH, et al. Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: Evidence for the involvement of sympathetic regulation. Schizophr Bull 2010;36:410-8.
32. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32 (Pubitemid 41587460)